At PainChek, we’re here to support you every step of the way. Find answers to frequently asked questions around PainChek’s technology, our partners, and the Government Grant.

FAQs

Contracted beds is a leading indicator of demand and these commercial agreements often take time to roll out and fully train the facilities and staff.
 
Pain assessments are a lagging indicator of clinical utility and we are almost at 140,000 assessments as at the end of June. That’s a strong indication of good growth in clinical utility.
 
Remember on average around 40-50% of residents are unable to self-report their pain and therefore need access to PainChek but we contract across all beds in a facility for ease of use – so that’s another factor that needs consideration.
 
Pain assessments are a duty of care in aged care and hospitals and are carried out as needed and clinical practice differs from one aged care home to another based on their protocols. So there is no average or standard to compare utility from one home to another.

It depends on the provider. This can be within a few days for smaller providers, ranging up to 4-6 weeks for larger providers. Once you're ready to get started with PainChek we begin the process of setting up your technology, integrating with your Care Management System, and getting all of your staff up to speed through a face to face and online training program.

The PainChek Government Grant is a federally funded initiative of world-first artificial intelligence technology. Australian Approved Residential aged care Providers are entitled to a free 12-month subscription to the PainChek tool. This is part of an Australian Government funded initiative to promote innovation in Aged Care and support improved pain assessment for people living with Dementia or other cognitive impairments.

PainChek® is a fast, accurate and consistent pain assessment tool for people use with people with cognitive impairment or dementia.

 

PainChek® uses the camera of a smart device to see and assess a person’s face, analysing it using an Artificial Intelligence (AI) system. The AI system then automatically recognises and documents facial muscle movements that are indicative of pain.

 

Next, the caregiver uses PainChek® to record their observations of pain related behaviours such as how the person is moving and vocalising in a simple binary (yes/no) format. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to quickly understand the levels of pain experienced by the person, and monitor the effect of medication and treatment over time.

 

PainChek is a truly global company, with clients in the United Kingdom, Australia, New Zealand and Singapore.
 
PainChek is continuing to expand its global footprint, with regulatory approval also granted in the EU, and regulatory review processes in progress in both the United States and Canada.

The science that underpins PainChek is an evolution of long-established clinical standards, underpinning the most commonly used pain assessment tools for people who are unable to self-report their own pain.
 
Derived from independent research conducted at Curtin University in WA by an international team, the principles on which PainChek operates, and the application itself, have been formally and extensively studied. The outcomes of these studies demonstrate not only the accuracy and consistency of PainChek, but also its value beyond the capabilities of historical tools.
 
In light of this, PainChek has been approved as a medical device in Australia, New Zealand, Singapore, the UK and the EU, with additional international approval processes currently in progress.
 
If you'd like to learn more about the research which underpins PainChek, you can click here  to view the full text of all PainChek clinical studies.

PainChek® is a software as a service technology that is deployed in the cloud and is not subject to territories or borders that can impact on supply to clients around the globe. PainChek can be downloaded as an App remotely by all clients, typically from the Apple Store or Google Play Store and installed without the need for direct faced to face contact, thereby minimising the impact of any potential supplier entry restrictions imposed by customers.

Though many of PainChek's clients operate in the residential aged care space, PainChek's approval as a medical device is not limited to those with cognitive impairment and dementia — PainChek's approval extends to the assessment of pain of anyone who is unable to self-report their own pain. This covers not only long term changes in cognitive ability, but also the impacts of short term deliriums and other conditions, making PainChek a powerful tool in residential aged care, home care, or an acute care setting.
 
Beyond PainChek's application in assessing the pain of adults, PainChek have developed an equivalent tool for the assessment of pain in pre-verbal children. Currently in clinical trials, the PainChek Children's app will give parents and carers never before seen insights into the pain of pre-verbal children, fundamentally changing the way pain management for children is approached.